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Background: Berberine, an isoquinoline alkaloid, has shown inhibitory effects on growth of several tumor cell lines
in vitro. The aim of this study was to investigate chemopreventive effects of berberine on intestinal tumor
development in Apcmin/+ mice.
Methods: Four-week old Apcmin/+ mice were treated with 0.05% or 0.1% berberine in drinking water for twelve
weeks. The number and the size of tumors were measured to evaluate intestinal tumor development. Tissue sections
were prepared for PCNA and Ki-67 immunostaining to detect cell proliferation, and TUNEL assay and cleaved
caspase-3 immunostaining for apoptosis. Western blot analysis and immunostaining were performed to detect the
activation of Wnt and epidermal growth factor receptor (EGFR) signaling pathways and COX-2 expression in the
intestinal tumor cells. The prostaglandin E2 level in the small intestine was detected using ELISA.
Results: Compared with untreated Apcmin/+ mice, the total numbers of tumors in the small intestine and the colon
were reduced by 39.6% and 62.5% in 0.05% and 0.1% berberine-treated mice, respectively. The numbers of tumors
in proximal, middle, and distal segments of the small intestine in 0.1% berberine-treated mice were significantly
reduced by 53.7%, 55.3%, and 76.5% respectively. Berberine treatment also decreased the numbers of all sizes of
tumors (>2 mm, 1–2 mm, and <1 mm) in the small intestine. Berberine suppressed tumor cell proliferation and
increased apoptosis. Furthermore, berberine decreased the activation levels of Wnt and EGFR signaling pathways, and
down-regulated COX-2 expression in intestinal tumor cells and prostaglandin E2 production in the small intestine.
Conclusions: Berberine inhibits intestinal tumor development, which is correlated with its activity to suppress tumor
cell proliferation and increase apoptosis in Apcmin/+ mice. Down-regulation of Wnt and EGFR signaling pathways and
COX-2 expression by berberine may be involved in its anti-tumorigenic effects.
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Berberine, an isoquinoline alkaloid, is present in several
plants, such as Hydrastis canadensis (goldenseal), Berberis
aquifolium (Oregon grape), and Berberis vulgaris
(barberry). Berberine has a wide range of pharmacologic ef-
fects, including antimicrobial activities, lipid-lowering effi-
cacy, and regulation of inflammatory responses [1,2].
Recent studies have demonstrated that berberine has an-
tineoplastic effects on several tumor cell lines in vitro,
including gastrointestinal and liver tumor cells, through* Correspondence: gi.tmuh@yeah.net
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reproduction in any medium, provided the orinhibiting cancer cell proliferation, inducing caspase-
dependent/independent apoptosis, and attenuating re-
active oxygen species production [3-7].
However, information regarding berberine’s effects on
intestinal tumor development in vivo remains limited.
The Apcmin/+ mouse carries a germline mutation of the
mouse adenomatous polyposis coli (Apc) gene. The Apc
gene is a tumor-suppressor gene homologous to the hu-
man Apc, and mouse carrying this mutation can spon-
taneously develop multiple tumors in the intestine [8,9].
Since the Apc gene mutation plays a significant role in
the pathogenesis of familial adenomatous polyposis and
sporadic intestinal cancers in patients, Apcmin/+ mouse
model is considered as an ideal genetic animal model. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this model for studying chemopreventive effects of berbe-
rine on intestinal tumor development.
Several signaling pathways have been reported to pro-
mote tumor development in intestinal tumorigenesis,
including Wnt and epidermal growth factor receptor
(EGFR) [10-12]. Apc gene which functions to target
β-catenin for degradation has been linked to Wnt signa-
ling pathway. Importantly, it has been shown that Apc
deficiency is associated with increased EGFR activity in
intestinal tumor of Apcmin/+ mice [13]. Moreover, down-
regulation of these activated signaling pathways has been
reported to effectively inhibit growth of colon cancer
cells in humans and tumor formation in Apcmin/+ mice
[12,14]. This study was aimed to investigate chemopre-
ventive effects and potential mechanisms of berberine on
intestinal tumor development in Apcmin/+ mouse model.
Methods
Mice and treatment
Apcmin/+ mice on C57BL/6J background (purchased
from Animal Model Institution of Nanjing University,
P. R. China) were housed on a 12-h light and 12-h dark
cycle. According to dosages in published reports [2,4-6],
0.05% or 0.1% Berberine chloride (Sigma-Aldrich, St. Louis,
MO, USA) in drinking water was administered to 4-week
old Apcmin/+ mice for 12 weeks. Untreated Apcmin/+ mice
were used as the control. Mice were monitored daily for
signs of illness. Body weight was recorded weekly. All ani-
mal experiments were performed according to the protocol
approved by the Institutional Animal Care and Use Com-
mittee at Tianjin Medical University, Tianjin, P. R. China.
Analysis of intestinal tumor development
Analysis of intestinal tumor development was performed
as previously described [14-17]. The small intestine and
colon were examined using an Olympus SZX7 stereo
dissecting microscope. Tumors were categorized as large
(>2 mm), medium (1–2 mm), and small (<1 mm). The
number of tumors was recorded by the same investiga-
tor blinded to the treatment. Swiss-rolled whole small
intestine and colon and the liver and the kidney tis-
sues were fixed in 10% formalin for preparing Paraffin-
embedded tissue sections. Tissue sections were stained
with hematoxylin and eosin and observed under the light
microscope to assess tumor stage and toxicity of the
liver and the kidney. Tissue sections were also used for
immunostaining.
Immunohistochemistry
To unmask antigens, the small intestinal sections were
boiled for 15 min in Antigen Unmasking Solution (Vector
laboratories, Inc. Burlingame, CA, USA). Endogenous per-
oxidase activity was blocked by incubation of sections in3% H2O2 for 5 minutes. After blocking non-specific bin-
ding using 10% goat serum for 1 h, tissue sections were
incubated with primary antibodies, mouse monoclonal
anti-proliferating cell nuclear antigen (PCNA, Dako,
Glostrup, Denmark), Ki-67 (Novocastra, New Castle, UK),
and rabbit polyclonal anti-cleaved caspase-3 (Cell Signal-
ing Technology, Beverly, MA, USA), β-catenin (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), cyclin
D1 (Thermo Scientific Inc., Waltham, MA, USA), EGFR
and phospho-EGFR (Tyr1068) (p-EGFR, Cell Signaling),
phospho-extracellular-signal-regulated kinase (p-ERK, Cell
Signaling), phospho-Akt (p-Akt, Ser473) (Cell Signaling),
and cyclooxygenase-2 (COX-2, Cell Signaling). Then sec-
tions were incubated with peroxidase-labeled anti-mouse
IgG or anti-rabbit IgG antibody and developed using DAB.
The tissue sections were evaluated under the light micro-
scope by the same investigator blinded to the treatment.
At least three tumors in each mouse and five fields at 400X
for each tumor were randomly selected for counting the
number of positively stained cells. None of the selected
fields were overlapped. Data were quantified by calculating
percentage of the positive cell in each tumor, then obtain-
ing the average of the percentages of positive cells in each
tumor. A modified semiquantitative scoring system was
used to calculate COX-2 immunoreactivity scoring, a scale
of 0–4 for determining the percentage of positive cells
(0, no staining; 1+, <25% of the epithelium stain positive;
2+, 25–50% positive; 3+, 50–75% positive; and 4+, >75%
positive), and a scale of 0–3 for strength of intensity of
staining (0, no staining; 1+, mild; 2+, moderate; and 3+,
intense). The result was presented by the percentage
scale X the strength of intensity scale.
TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end la-
beling (TUNEL) assay (Roche Applied Science, Mannheim,
Germany) was used to detect apoptotic cells [14-16].
Apoptotic cells were determined by counting percentage
of positive-stained cells in five randomly selected fields in
each tumor. At least three tumors in each mouse were
randomly selected.
Preparation of tissue extracts
The tumor tissues from the distal small intestine were
solubilized using Cell Lytic™ MT mammalian tissue lysis/
extraction reagent (Sigma-Aldrich) and homogenized. The
lysates were centrifuged, and the supernatants were re-
tained as total tissue extracts.
Nuclear fractions were prepared using the Nuclear Ex-
traction Kit (Signosis, Inc., Sunnyvale, CA, USA). Briefly,
tumor tissues were cut into small pieces, rinsed twice
with PBS. Then tissues were solubilized in Buffer I work-
ing reagent (10 mmol/L HEPES (pH 7.9), 10 mmol/L
KCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, supplemented
Table 1 Effects of berberine on intestinal tumor multiplicity







Total number 30.63 ± 1.69 18.50 ± 1.51* 11.50 ± 2.05$, &
Small intestinal 28.00 ± 2.00 16.69 ± 1.03* 10.50 ± 1.77$, &
Proximal 8.38 ± 1.51 5.25 ± 1.16* 3.88 ± 0.64$, §
Middle 9.50 ± 1.77 5.56 ± 0.50* 4.25 ± 1.04$
Distal 10.13 ± 1.55 5.88 ± 0.83* 2.38 ± 0.92$, &
<1 mm 8.13 ± 0.83 6.81 ± 0.65# 5.25 ± 1.04$, §
1-2 mm 10.13 ± 1.36 6.19 ± 0.84* 3.25 ± 0.46$, &
>2 mm 9.75 ± 2.05 3.69 ± 1.03* 2.00 ± 0.76$, §
Colon 2.63 ± 0.74 1.81 ± 0.65# 1.00 ± 0.46$, §
*, P < 0.01 and #, P < 0.05, 0.05% berberine-treated vs untreated Apcmin/+ mice;
$, P < 0.01 and ※, P < 0.05, 0.1% berberine-treated vs untreated Apcmin/+ mice;
&, P < 0.01 and §, P < 0.05, 0.1% berberine vs 0.05% berberine-treated
Apcmin/+ mice.
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homogenized until a single cell suspension was observed
microscopically. After centrifugation, pellets were washed
and resuspended in Buffer I. After shaking and centrifuga-
tion, the nuclear pellets were resuspended in Buffer II
working reagent supplemented with 1 mmol/L DTT and
1 mmol/L protease inhibitor. Samples were centrifuged
and the supernatant (nuclear extract) was frozen at −80°C.
Western blot analysis
The protein concentrations were determined using
Bicinchoninic acid protein assay (Thermo Scientific Inc.).
The total cellular lysates and nuclear fractions were mixed
with Laemmli sample buffer for SDS-polyacrylamide gel
electrophoresis, and Western blot using primary anti-
bodies against β-catenin, EGFR, p-EGFR and COX-2, and
then blotted with horseradish peroxidase conjugated se-
cond antibodies. The membranes were visualized using
ECL (GE Healthcare, Bucks, UK). Anti-β-actin antibody
(Sigma-Aldrich) was used as a total cellular lysate loading
control. Anti-histone H3 antibody (Cell signaling) was used
as a nuclear protein loading control. The band density was
detected using an image processor program (Image J), and
was determined by comparing the density of the indicated
band to the internal control band of the same mouse.
ELISA
Normal distal small intestinal mucosal tissues were col-
lected for detecting the prostaglandin E2 level (PGE2)
using ELISA kit (Cayman Chemical Company, Ann
Arbor, MI, USA) according to the manufacturer’s in-
struction, as previously described [9].
Statistical analysis
Statistical analyses were performed using SPSS (version
13.0; Chicago, IL, USA) for Windows. Means and standard
deviation were calculated for continuous variables. The
multiplicity of intestinal tumors in each group was com-
pared using One-way ANOVA analysis, followed by a post
hoc multiple comparisons test. Student’s t-test was used to
compare the percentage of positively stained cells or the
fold changes of the ratio for the relative density of bands
of berberine-treated group with those of untreated group.
The level of statistically significance was set at two-tailed
P < 0.05.
Results
Evaluation of side effects in Apcmin/+ mice treated with
berberine
There was no mortality throughout the treatment period
in untreated and in 0.05% and 0.1% berberine-treated
Apcmin/+ mice. We did not find any difference of food and
fluid intake and growth rate in berberine-treated mice,
compared to untreated Apcmin/+ mice. No histopathologicalterations were found in the liver and the kidney of
berberine-treated mice. Thus, no significant side effects by
berberine treatment used in this study were found.
Berberine inhibits intestinal tumor development
in Apcmin/+ mice
We first evaluated tumor development in 16-week old
Apcmin/+ mice with or without 12-week berberine treat-
ment. Berberine significantly reduced the multiplicity of
intestinal tumor in Apcmin/+ mice in a dose-dependent
manner (Table 1, Figure 1). Compared with the total
number of tumor in the small intestine and the colon in
untreated Apcmin/+ mice (30.63 ± 1.69), 0.05% and 0.1%
berberine treatment significantly decreased the number
of tumor by 39.6% (18.50 ± 1.51, P < 0.01), and 62.5%
(11.50 ± 2.05, P < 0.01, Figure 1B), respectively. Berberine
reduced 62.0% and 31.2% of the number of colon tumor
in 0.05% and 0.1% treatment groups (Figure 1B). In
addition, tumor numbers in proximal, middle, and distal
portions of the small intestine in 0.1% berberine-treated
group were reduced by 53.7%, 55.3%, and 76.5%, respect-
ively, while those in 0.05% group were reduced by 37.4%,
41.5%, and 42.0%, respectively. The numbers of all sizes
of tumors (>2 mm, 1–2 mm, and <1 mm) in the small in-
testine were significantly reduced (Figure 1D). Adenomas
with or without low-grade dysplasia were found in the
small intestine and colon in untreated and berberine-
treated Apcmin/+ mice, and we did not find the diffe-
rence regarding tumor stage in these two groups
(data not shown).
Berberine suppresses cell proliferation and increases
apoptosis in intestinal tumors
To further evaluate mechanisms of berberine’s effects
on intestinal tumor development in Apcmin/+ mice, we
Figure 1 Berberine inhibits intestinal tumor development in Apcmin/+ mice. (A) Apcmin/+ mice (age, 4 weeks) were treated with berberine,
and sacrificed after 12 weeks. The representative gross appearance of the intestinal tumors from untreated and 0.1% berberine-treated Apcmin/+
mice was shown under an Olympus SZX7 stereo dissecting microscope. (B) The number of tumors/mouse in the small intestine and colon in
0.05% and 0.1% berberine-treated groups were compared with the untreated Apcmin/+ mice. (C-D) Tumor numbers in each section of the small
intestine, and size distribution in each group were also listed. Columns, mean from the ten mice in each group; bars, standard deviation. *, P < 0.01
and #, P < 0.05, 0.05% berberine-treated vs untreated Apcmin/+ mice; $, P < 0.01 and ※, P < 0.05, 0.1% berberine-treated vs untreated Apcmin/+ mice; &,
P < 0.01 and §, P < 0.05, 0.1% berberine vs 0.05% berberine-treated Apcmin/+ mice.
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We focused on comparison between samples from
untreated Apcmin/+ mice and 0.1% berberine-treated
group, which showed the higher degree inhibition of
intestinal tumor development. Immunostaining showed
that berberine significantly decreased PCNA (44.60 ±
2.88 vs 65.80 ± 3.27, by 32%) and Ki-67 (6.73 ± 2.16 vs
14.89 ± 2.75, by 55%) positive cells (Figure 2A-B), sug-
gesting that berberine inhibits tumor cell proliferation
in Apcmin/+ mice.
The apoptotic cells in tumors detected by TUNEL stain-
ing were significantly increased by 2.14 fold in berberine-
treated mice compared with that in the untreated mice
(10.52 ± 0.61 vs 4.92 ± 0.86, P < 0.01, Figure 2C). Moreover,
berberine treatment increased caspase-3 activation de-
tected by cleavage caspase-3 immunostaining of intestinal
tissues (8.18 ± 1.45 vs 3.60 ± 1.34, P < 0.01, Figure 2D).
Thus, these results suggest that inhibition of proliferation
and promotion of apoptosis by berberine may play a role
in the prevention of tumor development in Apcmin/+ mice.
Berberine regulates signaling pathways in intestinal
tumor of Apcmin/+ mice
We further studied the effects of berberine on signaling
pathways involved in tumor development. It has been re-
ported that cytoplasmic accumulation and nuclear trans-
location of β-catenin was found in Apcmin/+ mice, whichindicated the aberrant Wnt signaling. Immunostaining
showed that berberine treatment decreased the percent-
age of positive cells of β-catenin in cytoplasm and/or nu-
clear of intestinal tumor in Apcmin/+ mice (43.20 ± 1.63
vs 63.00 ± 3.08, P < 0.01, Figure 3A). Cell cycle arrest is
associated with the expression of cell cycle regulators.
Decreased cyclin D1, one of the key downstream mole-
cules of Wnt signaling, promotes G1 arrest. Berberine
reduced expression of cyclin D1 by 54% (24.80 ± 3.11 vs
54.40 ± 3.78, P < 0.01, Figure 3B). Furthermore, phos-
phorylation of EGFR, ERK, and Akt in intestinal tumors
was suppressed by berberine treatment. The average per-
centages of p-EGFR-positive cells in berberine and un-
treated groups were 4.05 ± 2.74 vs 18.80 ± 3.74 (P < 0.01,
Figure 3C), p-ERK-positive cells are 16.55 ± 1.54 vs
46.88 ± 7.25 (P < 0.01, Figure 3D), and p-Akt stained
cells were 42.13 ± 7.76 vs 77.60 ± 8.36 (P < 0.01, Figure 3E),
respectively.
Moreover, the protein band ratio was calculated by
comparing the relative density of the protein band on
Western blots for β-catenin, total EGFR, and p-EGFR to
that of internal control band from the same mouse. The
average ratio in control was set as 100%, the fold changes
of the ratio in treated mice were shown. The levels of
these proteins were reduced in tumors of berberine-
treated Apcmin/+ mice compared with that of untreated
group (P < 0.01, Figure 3F).
Figure 2 Berberine reduces proliferation and induced apoptosis in intestinal tumors of Apcmin/+ mice. (A-B) Distal small intestinal sections
from untreated and 0.1% berberine-treated mice were stained with PCNA and Ki-67. (C-D) Small intestinal segments from untreated and 0.1%
berberine-treated groups were processed for TUNEL and cleaved caspase-3 staining (400×). Data were quantified as mean percentage of positive
cells at five randomly selected fields in each sample. Scale bars, 50 μm. Columns, means from at least six mice in each group; bars, standard deviation.
*, P< 0.01, 0.1% berberine-treated vs untreated Apcmin/+ mice.
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production
Over expression of COX-2 and increased PGE2 pro-
duction were reported to be associated with chronicinflammation and cell proliferation. Berberine significantly
down-regulated COX-2 immunoreactivity in small intes-
tinal tumors of Apcmin/+ mice (3.38 ± 0.51 vs 7.60 ± 0.57,
P < 0.01, Figure 4A-B). The expression level of COX-2
Figure 3 Berberine treatment regulates signaling pathways in intestinal tumors of Apcmin/+ mice. (A-B) Immunohistochemical analyses of
tumors using antibodies against β-catenin and cyclinD1 from the distal small intestine of untreated and 0.1% berberine-treated mice were shown
(400×). Scale bars, 50 μm. Data were quantified as mean percentage of positive cells for β-catenin in cytoplasm and/or nuclear and cyclinD1 at
five randomly selected fields. (C-E) p-EGFR, p-ERK and p-Akt were also analyzed by immunohistochemical staining. Data were quantified as mean
percentage of positive cells. (F) Nuclear protein extracts were prepared from tumors, and analyzed by Western blot analysis using anti-β-catenin
antibody. Anti-histone H3 antibody was used as a nuclear protein loading control. Protein lysates were prepared and analyzed by Western blot
analysis using anti-total EGFR and p-EGFR antibodies, and anti-β-actin antibody was used as a protein loading control. The protein band ratio was
calculated by comparing the relative density of the protein band for β-catenin, total EGFR, and p-EGFR to that of internal control band from the
same mouse. The average ratio in control was set as 100%, the fold changes of the ratio in treated mice were shown. Columns, means from at
least six mice in each group; bars, standard deviation. *, P < 0.01, 0.1% berberine-treated vs untreated Apcmin/+ mice.
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Figure 4 Berberine down-regulates COX-2 expression and PGE2 production. (A-B) Tumors of the distal small intestine from untreated and
0.1% berberine-treated groups were immunostained using COX-2 antibody. Immunoreactivity scoring using a modified semiquantitative scoring
system was shown (400×). Scale bars, 50 μm. (C) Protein lysates were prepared from tumors and analyzed by Western blot analysis. Anti-β-actin
antibody was used as a protein loading control. The protein band ratio was calculated by comparing the relative density of the protein band on
Western blots for COX-2 to that of internal control band from the same mouse. The average ratio in control was set as 100%, the fold change of
the ratio in treated mice was shown. (D) PGE2 levels of normal mucosa from untreated and 0.1% berberine-treated groups were detected by
ELISA. Columns, means from at least six mice in each group for immunohistochemistry and Western blot analysis, and ten mice in each group for
ELISA assay; bars, standard deviation. *, P < 0.01, 0.1% berberine-treated vs untreated Apcmin/+ mice.
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Apcmin/+ mice, compared with that of untreated group
(P < 0.01, Figure 4C). Berberine also decreased PGE2
production, a downstream product of COX-2, in normal
mucosa (0.76 ± 0.08 vs 1.06 ± 0.10, P < 0.01; Figure 4D).
The results suggest that the inhibition of COX-2 and PGE2
production by berberine may play a role in chemopreven-
tion of intestinal tumorigenesis.
Discussion
Evaluation of ancient natural products that have been
widely used for specific diseases, including berberine,
has attracted attention to explore their broad clinical ap-
plications. Our studies suggest that berberine has the
potential to prevent the growth and recurrence of intes-
tinal precancerous lesions. Although aspirin and some
specific COX-2 inhibitors, such as celecoxib, have shown
chemopreventive effects on colonic tumor development
in animal model and some patients [9,18-21], the potential
gastrointestinal and cardiovascular side effects in patientslimit their long-term use [22,23]. Berberine has recently
emerged as a potential chemopreventive agent due to its
antineoplastic effects [3-7]. The in vitro activities of berber-
ine may not represent the in vivo effects. Therefore, it is
important to investigate the efficacy of berberine in vivo.
The present study provides information regarding ef-
fects of berberine on intestinal tumor development using
Apcmin/+ mice model. Berberine was well tolerated, and sig-
nificantly reduced the multiplicity of intestinal tumor in a
dose-dependent manner. Berberine reduced cell prolifera-
tion and induced apoptosis, which are associated with in-
hibition of Wnt and EGFR signaling pathways in intestinal
tumor of Apcmin/+ mice. Our data also showed that berber-
ine down-regulated COX-2 activity. These results, together
with the recent study of prevention of azoxymethane-
induced colon cancer by berberine in rats [24], support the
chemopreventive effects of berberine on intestinal tumor.
Excessive proliferation and insufficient apoptosis are
related to intestinal tumor development and progres-
sion [14,25-27]. We found that berberine inhibited cell
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mice by regulating signaling pathways involved in proli-
feration and apoptosis. Antiproliferative and proapopto-
tic effects play roles in inhibition of intestinal tumor
formation and growth by berberine. One of the most im-
portant observations in the present study is that larger
size tumors (>2 mm in the small intestine) were signifi-
cantly decreased by berberine, suggesting that berberine
exerts strong activity to limit progression of polyps.
Dysregulation of Wnt signaling pathway has been re-
ported to play a major role in intestinal tumorigenesis in
humans and Apcmin/+ mice [10,14,28]. Truncated APC
protein encoded by mutated gene causes cytoplasmic
accumulation and nuclear translocation of β-catenin to
transactivate T cell factor/lymphoid enhancer factor in
the nucleus, leading to increasing transcription of many
oncogenic genes including cyclin D1 [10]. Our data
showed that the increased expressions of β-catenin in
cytoplasm and nuclear in Apcmin/+ mice were significantly
decreased by berberine, which supports berberine’s role in
antiproliferative mechanisms. These results are in consis-
tence with the findings from the in vitro study showing
that berberine inhibits the proliferation of colon cancer
cells by inactivating Wnt/β-catenin signaling [29]. Further
studies are required to characterize the exact mechanisms
underlying berberine’s inhibitory effects on Wnt signaling,
such as whether berberine inhibits β-catenin translocation
into the nucleus or enhances β-catenin degradation.
EGFR signaling pathway activation is another key
process in the development and progression of many
tumors, including intestinal cancer [30]. Interestingly,
Roberts et al. reported that Apcmin/+ mice carrying an
EGFR mutation with a marked reduction in EGFR activ-
ity had a 90% reduction in intestinal tumor compared
with Apcmin/+ mice expressing normal EGFR [31]. Re-
cently, increasing evidence indicates that both Wnt and
EGFR signaling pathways mediate β-catenin activa-
tion [32]. Aberrant Wnt pathway triggers pro-survival/
anti-apoptotic signaling cascades activation such as
phosphatidylinositol 3-kinase/Akt pathway [33,34]. We
analyzed the activation of EGFR signaling pathway in in-
testinal tumors of Apcmin/+ mice. Importantly, berberine
treatment could significantly suppress EGFR activation
and its downstream targets ERK and Akt. Therefore, we
hypothesize that berberine inhibits intestinal tumor deve-
lopment in Apcmin/+ mice through concomitant suppres-
sion of EGFR pathway, leading to decreasing tumor cell
proliferation and increasing apoptosis.
Over expression of COX-2 and increased PGE2 pro-
duction were reported to be associated with chronic
inflammation and endothelial cell proliferation by releas-
ing various angiogenic factors [35,36], and boosting PGE2
production was also shown to be related to the polyps
expansion [37]. Thus, the inhibition of COX-2 and PGE2production by berberine may also play a role in chemo-
prevention of intestinal tumorigenesis.
Conclusions
The present study shows that berberine treatment signifi-
cantly suppresses spontaneous intestinal tumor develop-
ment in Apcmin/+ mice, inhibits tumor cell proliferation,
and induces apoptosis, which are associated with berbe-
rine’s activity to inhibit signaling pathways involved
in tumor development. Thus, berberine may be a relatively
nontoxic and low-cost agent to prevent intestinal tumor
development.
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